ASH 2022 Conference Coverage
ASH 2022 Efficacy & Safety of Add-On Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Pts With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
By
ASH 2022 Conference Coverage
FEATURING
Abdulraheem Yacoub
By
ASH 2022 Conference Coverage
FEATURING
Abdulraheem Yacoub
Login to view comments.
Click here to Login
